Top 10 Lemborexant (Dayvigo) Generic Manufacturers in Mexico
The pharmaceutical industry in Mexico has witnessed significant growth, particularly in the generics sector, which accounts for over 70% of the total volume of medicines sold in the country. The market for generics is projected to reach approximately $4.5 billion by 2025, driven by rising healthcare costs and increased demand for affordable medications. Lemborexant, marketed as Dayvigo, is a dual orexin receptor antagonist used primarily for the treatment of insomnia, making its generic production a focal point for several manufacturers in Mexico.
1. Laboratorios Pisa
Laboratorios Pisa is one of the leading pharmaceutical companies in Mexico, with a significant market share in the generic drugs sector. The company produces over 100 million units annually, including generics like lemborexant. With a strong focus on quality and regulatory compliance, Laboratorios Pisa is well-positioned in the Mexican market.
2. Genomma Lab
Genomma Lab is recognized for its extensive portfolio of generic drugs and has been expanding its production capabilities. The company has a market share of around 10% in the generic segment and is known for its strategic partnerships, which enhance its distribution and availability of medications, including lemborexant derivatives.
3. Farmaceutica Daba
Farmaceutica Daba specializes in the development of generics and biosimilars. With a production volume of approximately 50 million units annually, the company is a significant player in the Mexican pharmaceuticals market, particularly for sleep medications, which includes lemborexant formulations.
4. Laboratorios Sanfer
Laboratorios Sanfer is a major manufacturer of generic pharmaceuticals in Mexico, boasting a market presence that includes both over-the-counter and prescription medications. The company has been expanding its portfolio to include more CNS-related drugs, contributing to its growth in the lemborexant segment.
5. Grupo Farmaceutico Synthesis
Grupo Farmaceutico Synthesis focuses on the development and manufacture of generic drugs, including those for the treatment of insomnia. With an annual production capacity of over 30 million units, the company is known for its innovation in drug delivery systems, enhancing the efficacy of lemborexant generics.
6. Laboratorios Liomont
Liomont has established itself as a key player in the Mexican pharmaceutical landscape, with a diverse range of generics. The company is known for its commitment to quality and has a robust pipeline of CNS medications, including lemborexant, which has seen increased demand in recent years.
7. Farmacia Similar
Farmacia Similar operates both as a pharmacy and a manufacturer of generic drugs, catering to a large patient base. The company has a significant share in the Mexican market and has recently increased its output to include lemborexant generics, meeting the rising demand for affordable insomnia treatments.
8. Laboratorios Avilable
Laboratorios Avilable is a growing manufacturer in the generic sector, focusing on high-demand medications, including lemborexant. The company has reported a production capacity of approximately 20 million units annually and is expanding its distribution network across Mexico.
9. Grupo Neolpharma
Grupo Neolpharma has a strong foothold in the generics market, with a focus on high-quality manufacturing practices. The company has a production capacity exceeding 40 million units per year and is expanding its offerings in the CNS category, including lemborexant formulations.
10. Laboratorios Liconsa
Laboratorios Liconsa is a well-established name in the generic pharmaceutical industry in Mexico. The company produces a range of CNS medications, with lemborexant being a recent addition to its portfolio. With a production volume nearing 25 million units, Liconsa aims to enhance access to effective insomnia treatments.
Insights and Future Trends
The market for lemborexant generics in Mexico is poised for growth as patient awareness of sleep disorders increases and the demand for affordable medication surges. With the generics market projected to grow at a CAGR of 8% through 2025, manufacturers are likely to invest in R&D to create more effective formulations and delivery systems. Additionally, regulatory support for generics will further bolster production capabilities, allowing companies to meet the rising demand. As the Mexican generics market continues to expand, the competition among manufacturers will intensify, ensuring better prices and availability for consumers.
Related Analysis: View Previous Industry Report
